Compare
Reviva Pharmaceuticals Holdings, Inc. vs Aprea Therapeutics, Inc. vs Anixa Biosciences Inc vs Synlogic, Inc.
| Latest fiscal year | Reviva Pharmaceuticals Holdings, Inc. RVPH | Aprea Therapeutics, Inc. APRE | Anixa Biosciences Inc ANIX | Synlogic, Inc. SYBX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-10-31 | 2025-12-31 |
| Revenue | n/a | n/a | n/a | $0 |
| Revenue growth (YoY) | n/a | n/a | n/a | -100.0% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | n/a | n/a |
| Net margin | n/a | n/a | n/a | n/a |
| Net income | -$19.86M | -$12.60M | -$10.93M | -$1.00M |
| EPS (Diluted) | n/a | -$1.93 | -$0.34 | -$0.08 |
| Operating cash flow | -$24.59M | -$12.89M | -$7.17M | -$4.36M |
| Free cash flow | n/a | n/a | n/a | -$4.36M |
| Cash & equivalents | $14.44M | $14.60M | $1.24M | $14.67M |
| Total assets | $15.92M | $15.93M | $16.08M | $15.45M |
| Total liabilities | $7.28M | n/a | $2.13M | n/a |
| Shareholders' equity | $8.65M | $12.44M | $15.16M | $11.86M |
| Return on year-end equity | -229.7% | -101.3% | -72.1% | -8.5% |
| Shares outstanding | 5.87M | 8.19M | 33.01M | 11.70M |
Revenue, most recent five fiscal years
| Fiscal year | Reviva Pharmaceuticals Holdings, Inc. | Aprea Therapeutics, Inc. | Anixa Biosciences Inc | Synlogic, Inc. |
|---|---|---|---|---|
| Latest | n/a | n/a | $210.0K Ended 2024-10-31 | $0 Ended 2025-12-31 |
| 1 year earlier | n/a | n/a | $210.0K Ended 2023-10-31 | $8.0K Ended 2024-12-31 |
| 2 years earlier | n/a | n/a | n/a | $3.37M Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | $512.0K Ended 2021-10-31 | $1.18M Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | n/a | $1.75M Ended 2021-12-31 |